Published in Cancer Cytopathol on August 25, 2014
BRAF Mutations in an Italian Regional Population: Implications for the Therapy of Thyroid Cancer. Int J Endocrinol (2015) 0.75
Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature (2010) 6.13
A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration. Nat Cell Biol (2007) 2.85
Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res (2008) 2.52
Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol (2011) 2.33
Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res (2004) 2.17
Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience. Acta Neurochir (Wien) (2012) 1.99
Does the fine-needle aspiration diagnosis of "Hürthle-cell neoplasm/follicular neoplasm with oncocytic features" denote increased risk of malignancy? Diagn Cytopathol (2004) 1.88
BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab (2004) 1.79
Metastases to the thyroid gland: prevalence, clinicopathological aspects and prognosis: a 10-year experience. Clin Endocrinol (Oxf) (2007) 1.74
Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arch (2008) 1.71
p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch (2005) 1.69
Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin. J Clin Oncol (2010) 1.66
Epithelial E- and P-cadherins: role and clinical significance in cancer. Biochim Biophys Acta (2012) 1.64
Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study. Blood (2011) 1.62
Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer (2010) 1.58
Inhibition of telomerase in the endothelial cells disrupts tumor angiogenesis in glioblastoma xenografts. Int J Cancer (2008) 1.55
Role of p16/INK4a in gastrointestinal stromal tumor progression. Am J Clin Pathol (2004) 1.54
Molecular analysis of immunoglobulin variable genes in human immunodeficiency virus-related non-Hodgkin's lymphoma reveals implications for disease pathogenesis and histogenesis. Haematologica (2008) 1.54
Loss of caveolin-1 and gain of MCT4 expression in the tumor stroma: key events in the progression from an in situ to an invasive breast carcinoma. Cell Cycle (2013) 1.52
MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia. Leuk Lymphoma (2012) 1.51
Mutations of the BIK gene in human peripheral B-cell lymphomas. Genes Chromosomes Cancer (2003) 1.50
Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin. Leuk Lymphoma (2013) 1.47
Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression. Breast Cancer Res (2005) 1.47
Endothelial progenitor cell trafficking in human immunodeficiency virus-infected persons. AIDS (2010) 1.45
Primary plasma cell leukemia followed by testicular plasmacytoma. Int J Hematol (2011) 1.44
Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma. Histopathology (2010) 1.44
Endothelial progenitor cells in HIV-positive patients: what are we talking about? J Acquir Immune Defic Syndr (2013) 1.42
Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. J Pathol (2005) 1.40
Expression and prognostic significance of CK19 in canine malignant mammary tumours. Vet J (2009) 1.38
Fine-needle aspiration, an efficient sampling technique for bacteriological diagnosis of nonulcerative Buruli ulcer. J Clin Microbiol (2009) 1.34
Expression of monocarboxylate transporters 1, 2, and 4 in human tumours and their association with CD147 and CD44. J Biomed Biotechnol (2010) 1.32
BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis? BMC Cancer (2008) 1.30
Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours. Breast Cancer Res (2009) 1.28
Chordoma of the skull base: predictors of tumor recurrence. J Neurosurg (2003) 1.24
Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. Clin Cancer Res (2009) 1.22
Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation. Blood (2007) 1.19
The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma. Clin Cancer Res (2011) 1.18
SCF(β-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. J Exp Med (2012) 1.18
Increasing expression of monocarboxylate transporters 1 and 4 along progression to invasive cervical carcinoma. Int J Gynecol Pathol (2008) 1.18
Safety of video-assisted thyroidectomy versus conventional surgery. Head Neck (2005) 1.16
Aggressive papillary thyroid microcarcinoma: prognostic factors and therapeutic strategy. Clin Nucl Med (2013) 1.16
Role of the life span determinant P66(shcA) in ethanol-induced liver damage. Lab Invest (2008) 1.15
Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis. Haematologica (2009) 1.15
Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types. J Clin Pathol (2012) 1.14
Papillary thyroid microcarcinoma: extrathyroidal extension, lymph node metastases, and risk factors for recurrence in a high prevalence of goiter area. World J Surg (2010) 1.14
FOXA1 is a potential oncogene in anaplastic thyroid carcinoma. Clin Cancer Res (2009) 1.14
The prognostic value of CD147/EMMPRIN is associated with monocarboxylate transporter 1 co-expression in gastric cancer. Eur J Cancer (2009) 1.13
Nonoptical massive parallel DNA sequencing of BRCA1 and BRCA2 genes in a diagnostic setting. Hum Mutat (2013) 1.12
Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. J Clin Oncol (2007) 1.10
Molecular histogenesis of plasmablastic lymphoma of the oral cavity. Br J Haematol (2002) 1.10
Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer (2008) 1.08
Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis. Cancer (2010) 1.07
Possible involvement of hMLH1, p16(INK4a) and PTEN in the malignant transformation of endometriosis. Int J Cancer (2002) 1.07
Primary cerebral lymphomatoid granulomatosis: report of four cases and literature review. J Neurooncol (2009) 1.06
Is morphology alone able to predict BRAF-mutated malignancies on thyroid FNAC? Virchows Arch (2014) 1.06
Epigenetic silencing of SOCS3 identifies a subset of prostate cancer with an aggressive behavior. Prostate (2010) 1.06
Can a gene-expression classifier with high negative predictive value solve the indeterminate thyroid fine-needle aspiration dilemma? Cancer Cytopathol (2013) 1.06
P-cadherin is up-regulated by the antiestrogen ICI 182,780 and promotes invasion of human breast cancer cells. Cancer Res (2004) 1.05
Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms. Blood (2011) 1.05
A novel heterozygous HIF2AM535I mutation reinforces the role of oxygen sensing pathway disturbances in the pathogenesis of familial erythrocytosis. Haematologica (2008) 1.04
Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? Clin Colorectal Cancer (2011) 1.02
Vitamin D and the mammary gland: a review on its role in normal development and breast cancer. Breast Cancer Res (2012) 1.02
DNA repair polymorphisms might contribute differentially on familial and sporadic breast cancer susceptibility: a study on a Portuguese population. Breast Cancer Res Treat (2006) 1.02
PIKing the right isoform: the emergent role of the p110beta subunit in breast cancer. Virchows Arch (2010) 1.01
Monocarboxylate transporters 1 and 4 are associated with CD147 in cervical carcinoma. Dis Markers (2009) 1.01
Immunocytochemical evaluation of thyroid neoplasms on thin-layer smears from fine-needle aspiration biopsies. Cancer (2005) 1.01
Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia. Haematologica (2009) 0.99
P-cadherin is coexpressed with CD44 and CD49f and mediates stem cell properties in basal-like breast cancer. Stem Cells (2012) 0.99
DNA repair gene polymorphisms and susceptibility to familial breast cancer in a group of patients from Campinas, Brazil. Genet Mol Res (2005) 0.99
Apocrine carcinoma of the breast: a comprehensive review. Histol Histopathol (2013) 0.99
Telomerase inhibition impairs tumor growth in glioblastoma xenografts. Neurol Res (2006) 0.99
Analysis of BRCA1 and BRCA2 mutations in Brazilian breast cancer patients with positive family history. Sao Paulo Med J (2005) 0.99
Molecular alterations of KIT oncogene in gliomas. Cell Oncol (2007) 0.99
Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome. Blood (2012) 0.98
p40: a p63 isoform useful for lung cancer diagnosis - a review of the physiological and pathological role of p63. Acta Cytol (2012) 0.98
Evaluation of hilar biliary strictures by using a newly developed forward-viewing therapeutic echoendoscope: preliminary results of an ongoing experience. Gastrointest Endosc (2009) 0.97
Establishing tumor cell lines from aggressive telomerase-positive chordomas of the skull base. Technical note. J Neurosurg (2006) 0.97
Expression of EGFRvIII in glioblastoma: prognostic significance revisited. Neoplasia (2011) 0.97